brentuximab vedotin   Click here for help

GtoPdb Ligand ID: 6772

Synonyms: Adcetris® | anti-CD30 ADC SGN-35 | SGN 35
Approved drug Immunopharmacology Ligand
brentuximab vedotin is an approved drug (FDA (2011), EMA (2012))
Compound class: Antibody
Comment: Antibody-drug conjugate (ADC) that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). The PubChem ID for the MMAE component compound is CID 11542188. The invention of this ADC is claimed in patent US7090843 [4] and the original article describing the parent antibody (C10 or AC10) is [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Immunopharmacology Comments
Brentuximab vedotin is an ADC targeting CD-30 positive tumour cells.
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic scleroderma Disease Ontology: DOID:418
OMIM: 181750
Orphanet: ORPHA90291
 Phase 1/2 clinical candidate for systemic sclerosis- see NCT03222492 and NCT03198689
Mastocytosis Disease Ontology: DOID:350
 Phase 2 clinical candidate for aggressive systemic mastocytosis, mast cell leukemia and systemic mastocytosis- see NCT01807598
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
 Ex Phase 2 clinical candidate for adults with SLE- trial NCT02533570 was terminated
Mycosis fungoides OMIM: 254400
Orphanet: ORPHA2584
 Approved drug for CD-30 positive MF. 3
Anaplastic large cell lymphoma Disease Ontology: DOID:0050744
 Approved drug for systemic anaplastic large cell lymphoma, and primary cutaneous ALCL.
Lymphoma, Hodgkin, Classic; CHL Disease Ontology: DOID:8567
OMIM: 236000
 Approved drug for HL.